Novartis' pelacarsen misses its cardiovascular endpoint, erasing CHF4.9 billion and raising the bar for every Lp(a) rival

SentiSense · Published Sep 7, 2026, 4:23 AM ET · Updated Sep 28, 2026, 2:45 AM ET

Novartis' pelacarsen failed the primary cardiovascular-outcomes endpoint of the 8,323-patient Lp(a)HORIZON trial, erasing roughly CHF4.9 billion of ma...